The FDA has announced Orphan Drug Designation for Imfinzi (durvalumab) to treat small cell lung cancer in combination with other therapies.
The post FDA grants Orphan Drug Designation to Imfinzi for SCLC appeared first on European Pharmaceutical Review.
Original Article: FDA grants Orphan Drug Designation to Imfinzi for SCLC